Your session is about to expire
← Back to Search
Cognitively Normal for Memory Loss (Bio-Hermes-002 Trial)
N/A
Waitlist Available
Research Sponsored by GAP Innovations, PBC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 3 years
Awards & highlights
Summary
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Eligible Conditions
- Memory Loss
- Mild Cognitive Impairment
- Alzheimer's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Biomarkers and PET
Study-wide Amyloid Positivity
Trial Design
3Treatment groups
Experimental Treatment
Group I: Mild-to-Moderate AD DementiaExperimental Treatment2 Interventions
A diagnosis of Mild-to-Moderate AD Dementia based on the National Institute of Aging (NIA) criteria and verified through medical records.
Group II: Mild Cognitive ImpairmentExperimental Treatment2 Interventions
A diagnosis of Mild Cognitive Impairment (MCI) based on the National Institute of Aging (NIA) criteria and verified through medical records.
Group III: Cognitively NormalExperimental Treatment2 Interventions
No reported memory loss or concerns as reported by participant and study partner.
Find a Location
Who is running the clinical trial?
GAP Innovations, PBCLead Sponsor
1 Previous Clinical Trials
1,002 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger